All secondary end points showed TCZ-SC to be superior to PBO-SC , including ACR@ and ACR@ response ( @ % and @ % for TCZ-SC , respectively , and @ % and @ % for PBO-SC , respectively ; P < @ for both ) and Disease Activity Score in @ joints ( DAS@ ) remission ( DAS@ < @ ; @ % versus @ % -LSB- P < @ -RSB- ) .